Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is scheduled to announce its earnings results after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.09) by $1.12. On average, analysts expect Anthera Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) opened at $1.80 on Friday. Anthera Pharmaceuticals, Inc. has a twelve month low of $1.20 and a twelve month high of $22.48.

A number of brokerages recently issued reports on ANTH. Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Jefferies Group LLC reissued a “hold” rating and set a $1.75 price target (down from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $5.11.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.